Charlie Starnes

1.8k total citations
16 papers, 1.1k citations indexed

About

Charlie Starnes is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Charlie Starnes has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Charlie Starnes's work include Bone health and treatments (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Bone health and osteoporosis research (3 papers). Charlie Starnes is often cited by papers focused on Bone health and treatments (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Bone health and osteoporosis research (3 papers). Charlie Starnes collaborates with scholars based in United States and Canada. Charlie Starnes's co-authors include B Wiemann, Sheila Scully, Sean Morony, Paul J. Kostenuik, Casey Capparelli, Colin R. Dunstan, Gary Elliott, Giorgio Senaldi, Thomas C. Boone and Brian Varnum and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Charlie Starnes

16 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charlie Starnes United States 10 567 407 388 110 108 16 1.1k
Kalu U.E. Ogbureke United States 18 247 0.4× 85 0.2× 589 1.5× 52 0.5× 105 1.0× 43 1.4k
Özge Uluçkan United States 17 284 0.5× 252 0.6× 329 0.8× 13 0.1× 72 0.7× 25 907
Daisuke Kurotaki Japan 27 322 0.6× 1.1k 2.6× 725 1.9× 23 0.2× 104 1.0× 51 1.9k
Paola Bernabei Italy 19 420 0.7× 586 1.4× 256 0.7× 15 0.1× 38 0.4× 28 1.1k
Abdeljabar El Andaloussi United States 19 494 0.9× 812 2.0× 540 1.4× 27 0.2× 82 0.8× 36 1.7k
Catharine J. Andresen United States 17 181 0.3× 210 0.5× 253 0.7× 12 0.1× 93 0.9× 26 833
Yoshihiro Takemoto Japan 19 392 0.7× 172 0.4× 503 1.3× 34 0.3× 121 1.1× 44 1.2k

Countries citing papers authored by Charlie Starnes

Since Specialization
Citations

This map shows the geographic impact of Charlie Starnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlie Starnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlie Starnes more than expected).

Fields of papers citing papers by Charlie Starnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlie Starnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlie Starnes. The network helps show where Charlie Starnes may publish in the future.

Co-authorship network of co-authors of Charlie Starnes

This figure shows the co-authorship network connecting the top 25 collaborators of Charlie Starnes. A scholar is included among the top collaborators of Charlie Starnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlie Starnes. Charlie Starnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Shatzen, Edward, B Wiemann, Charlie Starnes, et al.. (2013). Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors. European Journal of Pharmacology. 712(1-3). 8–15. 16 indexed citations
2.
Coxon, Angela, Stephen A. Kaufman, Man Xu, et al.. (2012). Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models. Molecular Cancer. 11(1). 70–70. 19 indexed citations
3.
Freeman, Daniel J., Kevin S. McDorman, Carl J. Kozlosky, et al.. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer. 11(1). 47–47. 24 indexed citations
4.
5.
Kaufman, Stephen A., Man Xu, Hongyu Wang, et al.. (2010). Abstract 1380: Antitumor activity of motesanib alone and in combination with chemotherapy in xenograft models of human non-small cell lung cancer. Cancer Research. 70(8_Supplement). 1380–1380. 1 indexed citations
6.
Brake, Rachael, Charlie Starnes, John Lu, et al.. (2008). Effects of Palifermin on Antitumor Activity of Chemotherapeutic and Biological Agents in Human Head and Neck and Colorectal Carcinoma Xenograft Models. Molecular Cancer Research. 6(8). 1337–1346. 26 indexed citations
7.
Kruser, Tim J., Eric A. Armstrong, S. Huang, et al.. (2007). Panitumumab, a Fully Human Anti-EGFR Monoclonal Antibody, Augments Radiation Response in Xenograft Models of Upper Aerodigestive Tract Cancers. International Journal of Radiation Oncology*Biology*Physics. 69(3). S615–S616. 3 indexed citations
8.
Kaufman, Stephen A., Charlie Starnes, Angela Coxon, et al.. (2006). AMG 706 induces the rapid destruction of tumor microvessels in nude mice. Cancer Research. 66. 892–892. 2 indexed citations
9.
Jackson, Edward F., Emilio Esparza‐Coss, James A. Bankson, et al.. (2005). The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model. Journal of Clinical Oncology. 23(16_suppl). 3134–3134. 7 indexed citations
10.
Morony, Sean, Kelly Warmington, Stephen Adamu, et al.. (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology. 146(8). 3235–3243. 82 indexed citations
11.
Morony, Sean, Kelly Warmington, Stephen Adamu, et al.. (2005). The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. 11 indexed citations
12.
Freeman, Daniel J., Kevin S. McDorman, Tammy L. Bush, et al.. (2004). 313 Mono- and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters. European Journal of Cancer Supplements. 2(8). 95–96. 5 indexed citations
13.
Capparelli, Casey, Paul J. Kostenuik, Sean Morony, et al.. (2000). Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.. PubMed. 60(4). 783–7. 122 indexed citations
14.
Senaldi, Giorgio, Brian Varnum, Ulla M. Sarmiento, et al.. (1999). Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family. Proceedings of the National Academy of Sciences. 96(20). 11458–11463. 202 indexed citations
15.
Wiemann, B & Charlie Starnes. (1994). Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacology & Therapeutics. 64(3). 529–564. 342 indexed citations
16.
Starnes, Charlie. (1992). Coley's toxins in perspective. Nature. 357(6373). 11–12. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kalu U.E. Ogbureke Breakdown of academic impact, for papers by Özge Uluçkan Breakdown of academic impact, for papers by Daisuke Kurotaki Breakdown of academic impact, for papers by Paola Bernabei Breakdown of academic impact, for papers by Abdeljabar El Andaloussi Breakdown of academic impact, for papers by Catharine J. Andresen Breakdown of academic impact, for papers by Yoshihiro Takemoto
Rankless by CCL
2026